Epithalon (Epitalon)

Epithalon is sold online as a research chemical, is not FDA-approved for any use, and its core scientific claims come almost entirely from a single research group, not a broad independently-replicated evidence base. This page describes what's known — not dosing or usage guidance, and not a recommendation to use it. Talk to a doctor before considering it.

Epithalon (also spelled Epitalon; research code AEDG, for its four constituent amino acids) is a synthetic tetrapeptide based on epithalamin, a pineal-gland extract studied for decades by Russian researcher Dr. Vladimir Khavinson and colleagues. Its headline claimed mechanism is activating telomerase, the enzyme that rebuilds the protective telomere caps on chromosomes — the basis for its marketing around aging and longevity.

Nearly every preclinical and clinical study behind Epithalon's reputation was conducted by the Khavinson group itself, without independent confirmation from unaffiliated labs — the single biggest limitation on how much confidence the evidence base can support. The foundational claim that Epithalon activates telomerase rests on a 2003 in-vitro study from that group reporting induced telomerase activity and telomere elongation in cultured human fibroblasts, without the kind of detailed statistical reporting (fold-changes, confidence intervals) that would let outside researchers fully evaluate it. A 2011 attempt by a separate US research group to replicate the telomerase-activation finding, using commercially synthesized AEDG, found no significant effect. More recent independent work (Al-Dulaimi et al., 2025) reported telomere-length increases through multiple pathways, offering some outside validation — but the overall picture remains a research area still working toward reliable independent replication, not settled science.

Alzheimer's Drug Discovery Foundation — Cognitive Vitality Report on Epithalamin/Epithalon →

Epithalon has never been FDA-approved for any use in the United States. It was one of the peptides the FDA removed from its Category 2 "significant safety risk" compounding list effective April 22, 2026 — not approval, only a change in nomination status — and in the July 23–24, 2026 advisory committee meeting, the committee voted to recommend Epitalon for the compounding-permitted list, a recommendation that still requires formal FDA rulemaking (typically 8–24 months) before it would actually become legal to compound. Until then, it remains available only through unregulated research-chemical sellers.

FDA — Bulk Drug Substances Used in Compounding →

Alzheimer's Drug Discovery Foundation — Epithalamin and Epithalon: Cognitive Vitality For Researchers